Winqvist, M., Mozaffari, F., Palma, M., Eketorp Sylvan, S., Hansson, L., Mellstedt, H., . . . Lundin, J. (2016). Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): Effects on T cells and immune checkpoints. Cancer Immunol Immunother.

Winqvist, Maria, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg, und Jeanette Lundin. "Phase I–II Study of Lenalidomide and Alemtuzumab in Refractory Chronic Lymphocytic Leukemia (CLL): Effects On T Cells and Immune Checkpoints." Cancer Immunol Immunother 2016.

Winqvist, Maria, et al. "Phase I–II Study of Lenalidomide and Alemtuzumab in Refractory Chronic Lymphocytic Leukemia (CLL): Effects On T Cells and Immune Checkpoints." Cancer Immunol Immunother 2016.